This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gangneux, J.-P.
Right arrow Articles by Derouin, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gangneux, J.-P.
Right arrow Articles by Derouin, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1999, p. 172-174, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Experimental Evaluation of Second-Line Oral Treatments of Visceral Leishmaniasis Caused by Leishmania infantum

Jean-Pierre Gangneux,* Michael Dullin, Annie Sulahian, Yves Jean-Francois Garin, and Francis Derouin

Laboratoire de Parasitologie-Mycologie, Faculté de Médecine Lariboisière-Saint-Louis, Paris, France

Received 2 June 1998/Returned for modification 15 September 1998/Accepted 1 November 1998

In a murine model of Leishmania infantum visceral leishmaniasis, metronidazole, ketoconazole, fluconazole, itraconazole, and terbinafine were less effective than antimonial agents in reducing hepatic parasite load. Ketoconazole potentiated the effect of meglumine antimoniate reference therapy through its marked activity against spleen infection.

* Corresponding author. Mailing address: Laboratoire de Parasitologie-Mycologie, Faculté de Médecine Lariboisière-Saint-Louis, 15 rue de l'Ecole de Médecine, 75270 Paris Cedex 06, France. Phone: 33 1 43 29 65 25. Fax: 33 1 43 29 51 92. E-mail: jpgangneux{at}chu-stlouis.fr.

Antimicrobial Agents and Chemotherapy, January 1999, p. 172-174, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Amato, V. S., Tuon, F. F., Siqueira, A. M., Nicodemo, A. C., Neto, V. A. (2007). Treatment of Mucosal Leishmaniasis in Latin America: Systematic Review. Am J Trop Med Hyg 77: 266-274 [Abstract] [Full Text]  
  • Walzer, P. D., Ashbaugh, A. (2002). Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia. Antimicrob. Agents Chemother. 46: 514-516 [Abstract] [Full Text]  
  • Murray, H. W. (2001). Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197 [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»